Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug;106(4):301-305.
doi: 10.1177/0300891619887225. Epub 2019 Dec 18.

Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer patients: safety and efficacy. An Italian experience

Eufemia S Lutrino  1 , Laura Orlando  1 , Antonio Febbraro  2 , Marianna Giampaglia  3 , Claudio Zamagni  4 , Paola Schiavone  1 , Claudio Scavelli  5 , Gianluca Dima  6 , Palma Fedele  1 , Guido Giordano  2 , Domenico Bilancia  3 , Anna Maria Quaranta  1 , Daniela Rubino  4 , Gianfranco Filippelli  6 , Caterina Fontanella  7 , Chiara Caliolo  1 , Antonella Marino  1 , Nicola Calvani  1 , Pasqualinda Ferrara  1 , Saverio Cinieri  1
Affiliations

Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer patients: safety and efficacy. An Italian experience

Eufemia S Lutrino et al. Tumori. 2020 Aug.

Abstract

Background: Chemotherapy plus targeted therapy is the established treatment for human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer (BC). Limited data regarding the safety and activity of the combination of eribulin and trastuzumab (E/T) in pretreated HER2-positive advanced BC (ABC) are available. The aim of this observational, retrospective, multicenter study was to examine the tolerability and the clinical activity of E/T in this setting.

Methods: Patients treated with eribulin mesylate plus standard dose of trastuzumab were included. Data on overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety were reported.

Results: Between October 2012 and November 2015, 24 consecutive patients with HER2-positive ABC were included. All patients were heavily pretreated: the median number of prior chemotherapy regimens for ABC was 3 (range 2-9). The median number of cycles with E/T was 11.5 (range 2-26). The ORR was 41.7%. Median PFS was 5.4 months, median postprogression survival was 5.4 months, and median OS was 8 months. Neutropenia was the most common grade 3/4 clinical adverse event (16.7%).

Conclusions: Tolerability and clinical activity of the E/T combination schedule are encouraging. The results of this study indicate that this combination might be considered for treatment of pretreated HER2 ABC.

Keywords: Eribulin; HER2-positive breast cancer; trastuzumab.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interests: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Kaplan-Meier analysis of time-to-event endpoints. (A) Progression-free survival (PFS). (B) Overall survival (OS).
See this image and copyright information in PMC

References

    1. Fitzmaurice C, Allen C, Barber RM, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol 2016; 3: 524–548. - PMC - PubMed
    1. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/Neu oncogene. Science 1987; 235: 177–182. - PubMed
    1. Andrulis IL, Bull SB, Blackstein ME, et al. Neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer: Toronto Breast Cancer Study Group. J Clin Oncol 1998; 16: 1340–1349. - PubMed
    1. Sjogren S, Inganas M, Lindgren A, et al. Prognostic and predictive value of cerbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 1998; 16: 462–469. - PubMed
    1. Andersson M, Lidbrink E, Bjerre K, et al. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J Clin Oncol 2011; 29: 264–271. - PubMed

MeSH terms